Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;1(2):10.20935/acadonco7456.
doi: 10.20935/acadonco7456. Epub 2024 Dec 19.

Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects

Samuel Auger  1 , Vasudha Mishra  2 , Alka Singh  2 , Yuxuan Miao  3 , Nishant Agrawal  1 , Evgeny Izumchenko  2
Affiliations

Circulating tumor DNA in head and neck squamous cell carcinoma-current status and future prospects

Samuel Auger et al. Acad Oncol. 2024.

Abstract

Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck. Stagnating survival rates in recent decades, despite advances in the treatment paradigms, surveillance technologies, and multidisciplinary care, leave clinicians with a need for better options for screening, risk-stratifying, and monitoring patients. A growing proportion of patients with HPV-associated SCC have improved outcomes but continue to have a heterogenous response to treatment. Advances in the platforms and assays measuring circulating tumor DNA offer an opportunity to monitor disease status at the molecular level for both virally mediated and traditional risk-factor-driven SCC of the head and neck. This overview will discuss experimental, clinically used, and commercially available liquid biopsy platforms and their recent applications in patients with head and neck SCC malignancies.

Keywords: circulating tumor DNA; head and neck cancer; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no conflicts of interest.

References

    1. Shanmugam A, Hariharan AK, Hasina R, Nair JR, Katra-gadda S, Irusappan S, et al. Ultrasensitive detection of tumor-specific mutations in saliva of patients with oral cavity squamous cell carcinoma. Cancer. 2021;127(10):1576–89. doi: 10.1002/cncr.33393 - DOI - PMC - PubMed
    1. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104. - PMC - PubMed
    1. Ishikawa S, Sugimoto M, Kitabatake K, Sugano A, Nakamura M, Kaneko M, et al. Identification of salivary metabolomic biomarkers for oral cancer screening. Sci Rep. 2016;6(1):31520. doi: 10.1038/srep31520 - DOI - PMC - PubMed
    1. He L, Ping F, Fan Z, Zhang C, Deng M, Cheng B, et al. Salivary exosomal miR-24-3p serves as a potential detective biomarker for oral squamous cell carcinoma screening. Biomed Pharmacother. 2020;121:109553. - PubMed
    1. Rapado-González Ó, Salta S, López-López R, Henrique R, Suárez-Cunqueiro MM, Jerónimo C. DNA methylation markers for oral cancer detection in non- and minimally invasive samples: A systematic review. Clin Epigenetics. 2024;16(1):105. doi: 10.1186/s13148-024-01716-9 - DOI - PMC - PubMed

LinkOut - more resources